Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM
2024-511580-28-02Phase 3Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of metformin, colchicine and minocycline in post-COVID syndrome (4 arms), sponsored by University Medical Center Utrecht. Primary endpoint: PROMIS-29 physical health summary score at 12 weeks. Planned start Feb 2025; status: authorised.
02
Drugs
metformincolchicineminocycline
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2024-511580-28-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511580-28-02.